Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy
Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology. SSc causes damage to the skin and various organs including the lungs, heart, and digestive tract, but the extent of the damage varies from patient to patient. The pathology of SSc includes ischemia, inflammation, and fibros...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/5/1104 |
| _version_ | 1797535219008405504 |
|---|---|
| author | Yoshihito Shima |
| author_facet | Yoshihito Shima |
| author_sort | Yoshihito Shima |
| collection | DOAJ |
| description | Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology. SSc causes damage to the skin and various organs including the lungs, heart, and digestive tract, but the extent of the damage varies from patient to patient. The pathology of SSc includes ischemia, inflammation, and fibrosis, but the degree of progression varies from case to case. Many cytokines have been reported to be involved in the pathogenesis of SSc: interleukin-6 is associated with inflammation and transforming growth factor-β and interleukin-13 are associated with fibrosis. Therapeutic methods to control these cytokines have been proposed; however, which cytokines have a dominant role in SSc might differ depending on the extent of visceral lesions and the stage of disease progression. Therefore, it is necessary to consider the disease state of the patient to be targeted and the type of evaluation method when an anti-cytokine therapy is conducted. Here, we review the pathology of SSc and potential cytokine targets, especially interleukin-6, as well as the use of anti-cytokine therapy for SSc. |
| first_indexed | 2024-03-10T11:42:21Z |
| format | Article |
| id | doaj.art-65f052ab6b6c4f7896a00917e3c8c958 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T11:42:21Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-65f052ab6b6c4f7896a00917e3c8c9582023-11-21T18:23:17ZengMDPI AGCells2073-44092021-05-01105110410.3390/cells10051104Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine TherapyYoshihito Shima0Laboratory of Thermo-therapeutics for Vascular Dysfunction, Osaka University Graduate School of Medicine, 3-1 Yamada-oka, Suita, Osaka 567-0871, JapanSystemic sclerosis (SSc) is a connective tissue disease of unknown etiology. SSc causes damage to the skin and various organs including the lungs, heart, and digestive tract, but the extent of the damage varies from patient to patient. The pathology of SSc includes ischemia, inflammation, and fibrosis, but the degree of progression varies from case to case. Many cytokines have been reported to be involved in the pathogenesis of SSc: interleukin-6 is associated with inflammation and transforming growth factor-β and interleukin-13 are associated with fibrosis. Therapeutic methods to control these cytokines have been proposed; however, which cytokines have a dominant role in SSc might differ depending on the extent of visceral lesions and the stage of disease progression. Therefore, it is necessary to consider the disease state of the patient to be targeted and the type of evaluation method when an anti-cytokine therapy is conducted. Here, we review the pathology of SSc and potential cytokine targets, especially interleukin-6, as well as the use of anti-cytokine therapy for SSc.https://www.mdpi.com/2073-4409/10/5/1104systemic sclerosisinterleukin-6interleukin-13tocilizumab |
| spellingShingle | Yoshihito Shima Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy Cells systemic sclerosis interleukin-6 interleukin-13 tocilizumab |
| title | Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy |
| title_full | Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy |
| title_fullStr | Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy |
| title_full_unstemmed | Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy |
| title_short | Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy |
| title_sort | cytokines involved in the pathogenesis of ssc and problems in the development of anti cytokine therapy |
| topic | systemic sclerosis interleukin-6 interleukin-13 tocilizumab |
| url | https://www.mdpi.com/2073-4409/10/5/1104 |
| work_keys_str_mv | AT yoshihitoshima cytokinesinvolvedinthepathogenesisofsscandproblemsinthedevelopmentofanticytokinetherapy |